Re: Covid-19: UK becomes first country to authorise antiviral molnupiravir
If NICE approves molnupiravir then surely it should approve a safer, more effective, cheaper and physiological agent.
The evidence base for "vitamin" D3 in innate and adaptive immunity is extensive and rapidly growing, For a recent over-view re Covid-19 see: https://www.researchgate.net/publication/354376762_THE_INFLUENCE_OF_VITA...
D3 is not a drug, it has evolved and has physiology, and medical professors should question whether NICE or Cochrane should be empowered to dispute the use of D3 the basis of lack of big RCTs. D3 impacts a large range of diseases, and most academic medical departments ( and dental) seek to understand and treat conditions that are exacerbated by physiological D3-deficiency. If D3-ignoring continues much longer I have in mind a book "Medicine's Worst Ever (ongoing) Mistake".
Competing interests: No competing interests